Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 1,202,807 shares, a growth of 22.3% from the December 31st total of 983,877 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily trading volume, of 285,256 shares, the short-interest ratio is presently 4.2 days. Based on an average daily trading volume, of 285,256 shares, the short-interest ratio is presently 4.2 days. Approximately 1.5% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.00.

Institutional Trading of Citius Oncology

Several large investors have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of Citius Oncology in the 3rd quarter worth about $36,000. Bank of America Corp DE raised its stake in Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after buying an additional 8,411 shares in the last quarter. Arkadios Wealth Advisors bought a new position in Citius Oncology during the 2nd quarter worth approximately $51,000. IFP Advisors Inc grew its position in shares of Citius Oncology by 49.5% in the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock worth $67,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Citius Oncology by 179.0% in the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after acquiring an additional 36,758 shares during the last quarter. Institutional investors and hedge funds own 70.52% of the company’s stock.

Citius Oncology Stock Performance

Shares of Citius Oncology stock traded up $0.03 during trading hours on Tuesday, hitting $1.11. The company’s stock had a trading volume of 46,571 shares, compared to its average volume of 209,700. The business has a fifty day moving average of $1.14 and a 200 day moving average of $1.54. Citius Oncology has a 1-year low of $0.55 and a 1-year high of $6.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.56 and a quick ratio of 0.11.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06).

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.